High Tide assessing U.S. licensing pathways for Canna Cabana retail brand

High Tide (HITI) welcomed the Executive Order issued by the White House advancing the rescheduling of cannabis as well as an announcement that the Centers for Medicare & Medicaid Services is expected to launch a pilot program allowing certain Medicare beneficiaries to receive CBD treatments at no cost. “Given the imminent move toward cannabis rescheduling, the Company has begun evaluating the feasibility of expanding its flagship bricks-and-mortar retail brand, Canna Cabana, into the United States through a licensing model. In parallel, the Company’s hemp-derived CBD brands, NuLeaf Naturals and FAB CBD, are well-positioned to benefit from rescheduling and the potential inclusion of CBD products within Medicare Advantage supplemental benefits. This positioning is supported by THC-free and broad-spectrum product formats that align with compliant Medicare benefit catalogs, CGMP-certified operations, and USDA organic product certifications. NuLeaf’s breadth, scale, and premium positioning enable long-term category leadership through a dedicated, Medicare-ready offering, while FAB’s purpose-driven, simplified dosing assortment is designed to support faster adoption across Medicare Advantage plans. Both NuLeaf and FAB will begin evaluating Medicare-aligned product categories as a result of today’s news. In addition, the Company is pleased to announce that it has reengaged IR Agency effective December 19, 2025, to provide investor relations services, supporting the Company’s communications with existing and prospective shareholders, the investment community and stakeholders,” the company stated.